Portfolio Companies

Portfolio Companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
(NASDAQ: ACHN)
New Haven, CT
Innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease
(NASDAQ: FOLD)
Cranbury, NJ
Developing small molecule, orally active drugs to treat lysosomal storage disorders using pharmacological chaperones to selectively bind and "rescue" misfolded target proteins
Ewing, NJ
Advanced computational fragment-based drug design technology for lead generation and optimization
Pittsboro, NC
Biolex is developing a revolutionary system for the recombinant production of therapeutic proteins. The company’s business model has two major components: 1) development of proprietary “Biolex Proteins” and 2) co-development projects with other biopharma companies. The lead Biolex Protein is in Phase 2 trials for
Hepatitis C.
King of Prussia, PA
Uses a proprietary protein engineering platform and a modified form of transferrin to enhance half life, efficacy, and safety of proteins; initially targeting diabetes
Acquired by Pfizer in February 2007
Princeton, NJ
Identifies ratios of synergistic drug combinations in vitro, and fixes ratios in liposomal drug carriers for in vivo treatment of various cancers
Philadelphia, PA
Uses a platform, CB-CAPs (Cell-Bound Complement Activation Products), to develop an early identification and monitoring solution for autoimmune diseases
ACQUIRED BY CYPRESS BIOSCIENCE IN FEBRUARY 2009
(NASDAQ: CEMP)
Chapel Hill, NC
Developing drugs for difficult-to-treat and drug-resistant bacterial infections, including community-acquired bacterial pneumonia and MRSA infections
Lutherville, MD
Developing novel treatments for vascular diseases with an initial focus on pulmonary arterial hypertension
Conshohocken, PA
Uses Hepatocyte Directed Vesicles to deliver insulin for diabetes treatment
(NASDAQ: DSCO)
Warrington, PA
Developing a synthetic lung surfactant to aid lung development in premature infants
(NASDAQ: DRTX)
Morristown, NJ
Developing drugs to advance care in infectious disease, including Gram-positive acute bacterial skin and skin structure infections (abSSSI)
Bedminster, NJ
Specialty pharma company focused on the acute care setting, treating conditions in cardiology, thrombolytic, and oncology supportive care areas
ACQUIRED BY CORNERSTONE THERAPEUTICS IN JUNE 2012
Eximias Pharmaceutical Corporation
Berwyn, PA
Developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA
Acquired by YM Biosciences in May 2006
(NASDAQ: HZNP)
Deerfield, IL
Developing and commercializing drugs to target unmet therapeutic needs in arthritis, pain and inflammatory diseases
(NASDAQ: INSM)
Monmouth Jct., NJ
Developing inhaled therapeutics to treat chronic respiratory infections, with additional programs for treatment of neuromuscular and metabolic disorders
TRANSAVE MERGED WITH INSMED IN DECEMBER 2010
Wayne, PA
Medical device company developing a novel endovascular stapling device designed to optimize peripheral angioplasty results for the treatment of peripheral artery disease (PAD)
Pittsburgh, PA
Specialty pharmaceutical distributor, focused on high-cost injectables and infusibles that require special handling and strict adherence to prescribed treatment protocols
Acquired by Walgreen Co. in July 2006
Bristol, PA
Development of a proprietary and patented drug/device technology for treatment of onychomycosis
Malvern, PA
Developing novel oncolytic viruses to treat cancer
Malvern, PA
Developing and commercializing Transcranial Magnetic Stimulation, a noninvasive medical technology, to treat psychiatric and neurological disorders
Glen Burnie, MD
Provides at-home diagnostic testing of obstructive sleep apnea (OSA) as an alternative to in-laboratory sleep studies
(NASDAQ: PATH)
Conshohocken, PA
Specialty pharma company developing innovative products for the treatment of neurologic and psychiatric diseases
New York, NY
Funding early and growth stage digital health and healthcare IT companies developing cutting edge technologies in care coordination, patient engagement, analytics and message alerts
New Haven, CT
Developing therapeutics and diagnostics based on Complement Factor H (CFH) research to treat for the dry form of age related macular degeneration (AMD) and membranoproliferative glomerulonephritis type II (MPGN-II)
New York, NY
Integrated dermatology company commercializing prescription and consumer skincare products
Pittsburgh, PA
Personalized diagnostics enabling customized and predictive treatment decisions for cancer patients
Malvern, PA
Developing small molecule antibiotics to address increasing bacterial resistance and chronic or recurrent infections
Acquired by Novartis AG in July 2008
 
Lexington, MA
Provider of innovative single molecule and single cell analysis solutions that enable discovery of common and rare regions of genomic interest. Proprietary microdroplet technology has broad applications in genomic research, development of clinical diagnostics, compound screening, and biomarker detection
Morrisville, NC and Basking Ridge, NJ
Developing antidote-controlled antithrombotics via rational design of drug-antidote pairs, using modified RNA-based aptamers
Bedford, MA
Developing and commercializing automated rapid testing to detect microbiological contamination in the manufacture of pharmaceutical and personal care products.
Saddle Brook, NJ
Commercializing consumer products for female sexual health, including lead product Zestra®
Horsham, PA
Emerging growth services company revolutionizing the way pharmaceutical companies apply marketing information to their operations
ACQUIRED BY IMPACTRx IN SEPTEMBER 2011
Philadelphia, PA
Developing an oral formulation of calcitonin for the treatment of osteoporosis
Morrisville, NC
Clinical stage company developing a novel, office-based medical device to treat dry eye syndrome
(NASDAQ: TNGN)
East Norriton, PA
Developing human tissues and organs, derived from a patient's own cells, initially treating spina bifida and spinal cord injury with the neo-bladder
Malvern, PA
Developing novel, targeted drugs to treat cancer by regulating the apoptosis (programmed cell death) pathway
Durham, NC
Commercializing revolutionary medical device that enables minimally invasive single-incision, single-port surgery
(NASDAQ: TZYM)
Durham, NC
Developing novel, small molecule therapeutics for the treatment of gastrointestinal motility disorders.